Oppenheimer Maintains Outperform on HCA Healthcare, Raises Price Target to $400
Portfolio Pulse from Benzinga Newsdesk
Oppenheimer analyst Michael Wiederhorn has maintained an 'Outperform' rating on HCA Healthcare and raised the price target from $390 to $400.

October 28, 2024 | 12:52 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Oppenheimer has reaffirmed its 'Outperform' rating for HCA Healthcare and increased the price target to $400, indicating confidence in the company's performance.
The increase in price target from $390 to $400 by Oppenheimer suggests a positive outlook on HCA Healthcare's future performance. The 'Outperform' rating indicates that the analyst expects HCA to perform better than the market average, which is likely to positively influence investor sentiment and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100